FrancophonIA/ELRC3.0 huggingface dataset:
English: • As the MULTAQ Information Card does not include all warnings or contraindications, the SPC should be referred to prior to prescribing MULTAQ and also prior to prescribing additional drugs to a patient already taking MULTAQ.
Estonian: • Kuna MULTAQ'i teabekaart ei sisalda kõiki hoiatusi või vastunäidustusi, peab enne MULTAQ'i väljakirjutamist tutvuma ravimi omaduste kokkuvõttega ning samuti enne täiendavate ravimite väljakirjutamist patsiendile, kes juba võtab MULTAQ'it.
English: The MULTAQ Information Card should contain a list of drugs which interact with MULTAQ classified according to the seriousness of the interaction (eg contraindication, not recommended, use with caution).
Estonian: MULTAQ'i teabekaart peab sisaldama nimekirja ravimitest, millel on koostoime MULTAQ'iga, klassifitseeritult koostoime tõsidusele (nt vastunäidustus, ei ole soovitav, kasutada ettevaatusega).
English: • That MULTAQ must not be used in patients with unstable haemodynamic conditions including patients with symptoms of heart failure at rest or with minimal exertion (corresponding to NYHA class IV and unstable class III patients).
Estonian: • MULTAQ'it ei tohi kasutada ebastabiilses hemodünaamilises seisundis patsientidel, kaasa arvatud patsiendid, kellel on südamepuudulikkuse sümptomid rahuolekus või minimaalse pingutuse korral (vastavalt NYHA IV klassi ja III klassi ebastabiilsed patsiendid).
English: If ALT levels are confirmed to be ≥3 × ULN after re-measurement, treatment with dronedarone should be withdrawn.
Estonian: Kui kontrollanalüüsis leiab kinnitust, et ALAT on ≥ 3 × ULN, tuleb ravi dronedarooniga lõpetada.
English: The Marketing Authorisation Holder shall ensure that Health care professionals who intend to prescribe or dispense MULTAQ are provided with an SPCand the MULTAQ Information Card.
Estonian: Müügiloa hoidja peab tagama, et tervishoiutöötajad, kes kavatsevad määrata ravi MULTAQ'iga või kasutada seda, varustatakse ravimi omaduste kokkuvõtte ja MULTAQ'i teabekaardiga.
English: • That liver function tests should be performed prior and during treatment.
Estonian: • Enne ravi algust ja ravi ajal tuleb teha maksafunktsiooni laboratoorsed uuringud.
English: The content and format of the MULTAQ Information Card, together with the communication and distribution plan should be agreed with the National Competent Authority in each Member State prior to distribution.
Estonian: Igas liikmesriigis tuleb MULTAQ'i teabekaardi sisu ja formaat, sh kommunikatsiooni ja turuletoomise plaan, kooskõlastada rahvusliku Ravimiametiga enne ravimi turuletoomist.
English: o potential torsades de pointes inducers including phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides.
Estonian: o potentsiaalselt torsades de pointes indutseerivad ravimid, kaasaarvatud fenotiasiinid, tsisapriid, bepridiil, tritsüklilised antidepressandid, terfenadiin ja teatud suukaudsed makroliidid.
English: • Use with caution: in association with digoxin, beta blockers, calcium antagonists, statins and vitamin K antagonists.
Estonian: • Kasutada ettevaatlikult koos digoksiini, beetablokaatorite, kaltsiumi antagonistide, statiinide ja vitamiin K antagonistidega.
English: • Contraindication: o CYP3A inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir.
Estonian: • Vastunäidustus: o CYP3A inhibiitorid, kaasaarvatud ketokonasool, itrakonasool, vorikonasool, posakonasool, telitromütsiin, klaritromütsiin, nefasodoon ja ritonavir.
English: • Not recommended/to be avoided: o grapefruit juice, o potent CYP3A4 inducers including rifampicin, phenobarbital, carbamazepine, phenytoin, St John's Wort o dabigatran.
Estonian: • Ei soovitata/peab vältima: o greipfruudi mahl, o tugevatoimelised CYP3A4 indutseerijad, kaasaarvatud rifampitsiin, fenobarbitaal,
English: Kinzalmono telmisartan
Estonian: Kinzalmono telmisartaan
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.
Estonian: Euroopa Komisjon andis Kinzalmono müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. detsembril 1998.
English: What measures are being taken to ensure the safe and effective use of Kinzalmono?
Estonian: Mis meetmed võetakse, et tagada Kinzalmono ohutu ja efektiivne kasutamine?
English: The full EPAR for Kinzalmono can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Kinzalmono kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: A risk management plan has been developed to ensure that Kinzalmono is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Kinzalmono võimalikult ohutu kasutamine.
English: Other information about Kinzalmono
Estonian: Muu teave Kinzalmono kohta
English: Kinzalmono is a medicine that contains the active substance telmisartan.
Estonian: Kinzalmono on ravim, mis sisaldab toimeainena telmisartaani.
English: The CHMP decided that Kinzalmono's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Kinzalmono kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The doctor should monitor the patient's blood pressure closely when starting Kinzalmono, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Kinzalmono ravi alguses tähelepanelikult jälgima patsiendi vererõhku ning ta võib otsustada vererõhku vähendavat annust kohandada.
English: This is a summary of the European public assessment report (EPAR) for Kinzalmono.
Estonian: See on ravimi Kinzalmono Euroopa avaliku hindamisaruande kokkuvõte.
English: Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems.
Estonian: Hüpotensioon võib sagedamini esineda patsientidel, kes võtavad Kinzalmonot kardiovaskulaarhäirete ennetamiseks.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Kinzalmono must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Estonian: II tüüpi diabeediga patsiendid või mõõduka kuni raske neerukahjustusega patsiendid ei tohi Kinzalmonot kasutada koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kinzalmono, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Kinzalmono omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For the prevention of cardiovascular problems, 80 mg Kinzalmono once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Estonian: Kardiovaskulaarhäirete ennetamiseks uuriti üks kord ööpäevas manustatava 80 mg Kinzalmono annuse mõju ühes põhiuuringus, milles osales ligikaudu 26 000 vähemalt 55-aastast patsienti, kellel oli südame- või arterite haigus, oli olnud infarkt või kellel oli diabeet ja kardiovaskulaarhäirete suur risk.
English: For the treatment of essential hypertension, the usual recommended dose of Kinzalmono is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Estonian: Essentsiaalse hüpertensiooni raviks on tavaline soovitatav Kinzalmono annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka annusest 20 mg üks kord ööpäevas.
English: Various doses of Kinzalmono were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Estonian: Kinzalmono eri annuste toimet võrreldi platseebo (näiva ravimi) ja teiste kõrgvererõhuravimite (atenolool, lisinopriil, enalapriil, amlodipiin) toimega.
English: The active substance in Kinzalmono, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Kinzalmono toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: For more information about treatment with Kinzalmono, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Kinzalmonoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Kinzalmono was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Estonian: Kinzalmono toimet võrreldi ramipriili toimega (samuti kardiovaskulaarhäirete ennetamise ravim) ja mõlema ravimi koostoimega.
English: For the treatment of essential hypertension, Kinzalmono has been studied in 2,647 patients who took Kinzalmono either alone or in combination with hydrochlorothiazide.
Estonian: Essentsiaalse hüpertensiooni ravis uuriti Kinzalmonot 2647 patsiendil, kes võtsid kas ainult Kinzalmonot või Kinzalmonot koos hüdroklorotiasiidiga.
English: Kinzalmono must not be used in women who are more than three months pregnant.
Estonian: Kinzalmonot ei tohi kasutada rasedad pärast esimest kolme raseduskuud.
English: Why has Kinzalmono been approved?
Estonian: Miks Kinzalmono heaks kiideti?
English: Kinzalmono is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Kinzalmonot kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanud patsientidel.
English: Kinzalmono must not be used in people who have severe liver problems or bile problems.
Estonian: Kinzalmonot ei tohi kasutada ka patsiendid, kellel on rasked maksa- või sapihäired.
English: For the full list of all side effects reported with Kinzalmono, see the package leaflet.
Estonian: Kinzalmono kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the prevention of cardiovascular problems, Kinzalmono had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Estonian: Kardiovaskulaarhäirete ennetamisel sarnanes Kinzalmono toime ramipriili toimega: ligikaudu 17% patsientidest suri, vajas kardiovaskulaarhäirete tõttu haiglaravi või sai südameinfarkti või insuldi.
English: What is the risk associated with Kinzalmono?
Estonian: Mis riskid Kinzalmonoga kaasnevad?
English: In the treatment of essential hypertension, Kinzalmono was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Estonian: Essentsiaalse hüpertensiooni ravis oli Kinzalmono diastoolse vererõhu vähendamisel efektiivsem kui platseebo ning ravimi toime kõrgvererõhule sarnanes teiste kõrgvererõhuravimite toimega.
English: What is Kinzalmono?
Estonian: Mis on Kinzalmono?
English: Kinzalmono is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Estonian: Kinzalmonot kasutatakse ka kardiovaskulaarsete (südame-veresoonkonna) häirete, näiteks infarkti või insuldi ennetamiseks.
English: Side effects with Kinzalmono are not common.
Estonian: Kinzalmono kasutamisel esineb kõrvalnähte harva.
English: How does Kinzalmono work?
Estonian: Kuidas Kinzalmono toimib?
English: What is Kinzalmono used for?
Estonian: Milleks Kinzalmonot kasutatakse?
English: What benefit has Kinzalmono shown during the studies?
Estonian: Milles seisneb uuringute põhjal Kinzalmono kasulikkus?
English: How is Kinzalmono used?
Estonian: Kuidas Kinzalmonot kasutatakse?
English: How has Kinzalmono been studied?
Estonian: Kuidas Kinzalmonot uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Kinzalmono on retseptiravim.
English: The marketing authorisation was renewed on 17 August 2003 and on 17 August 2008.
Estonian: Müügiluba pikendati 17. augustil 2003 ja 17. augustil
English: The European Commission granted a marketing authorisation valid throughout the European Union for NovoNorm to Novo Nordisk A/S on 17 August 1998.
Estonian: Euroopa Komisjon andis NovoNormi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Novo Nordisk A/S 17. augustil 1998.
English: NovoNorm is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Estonian: NovoNormi ei soovitata kasutada alla 18-aastastel patsientidel, sest ohutuse ja efektiivsuse andmed selle vanuserühma kohta puuduvad.
English: NovoNorm is a medicine that contains the active substance repaglinide.
Estonian: NovoNorm on ravim, mis sisaldab toimeainena repagliniidi.
English: The Committee recommended that NovoNorm be given marketing authorisation.
Estonian: Komitee soovitas anda NovoNormile müügiloa.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOVONORM EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE NOVONORM Kokkuvõte üldsusele
English: Other information about NovoNorm:
Estonian: Muu teave NovoNormi kohta
English: The main studies compared NovoNorm with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
Estonian: Põhiuuringutes võrreldi NovoNormi muude II tüüpi suhkurtõve raviks kasutatavate ravimitega (glibenklamiid, glipitsiid või gliklatsiid).
English: Another study looked at the effect of adding NovoNorm to metformin.
Estonian: Ühes uuringus vaadeldi NovoNormi lisamise mõju ravile metformiiniga.
English: NovoNorm is taken before meals, normally up to 15 minutes before each main meal.
Estonian: NovoNormi manustatakse kuni 15 minutit enne iga põhisöögikorda.
English: NovoNorm doses may also need to be adjusted when given with some medicines used in heart conditions, and to treat pain, asthma and other conditions.
Estonian: Samuti võib osutuda vajalikuks kohandada NovoNormi annust, kui seda manustatakse koos mõne teise ravimiga, mida kasutatakse valu vaigistamiseks või astma või mõne muu tervisehäire raviks.
English: What is NovoNorm?
Estonian: Mis on NovoNorm?
English: For the full list of all side effects reported with NovoNorm, see the Package Leaflet.
Estonian: NovoNormi kohta teatatud kõrvalnähtude täieliku nimekirja leiate pakendi infolehelt.
English: If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Estonian: Juhul kui patsiendi raviks kasutati mõnda muud suhkurtõve ravimit, mis asendatakse NovoNormiga, on soovitatavaks algannuseks 1 mg.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that NovoNorm's benefits are greater than its risks for the treatment of type 2 diabetes.
Estonian: Inimravimite komitee jõudis otsusele, et NovoNormi kasulikkus II tüüpi suhkurtõve ravis on suurem kui sellega kaasnevad riskid.
English: In the study where NovoNorm was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
Estonian: Uuringus, kus NovoNorm lisati metformiinile, oli kahe ravimi kogutoime võrdne vähemalt nende ravimite üksiktoimete summaga.
English: In all studies, NovoNorm led to a decrease in the level of HbA1c, which showed that blood glucose levels had been controlled to a similar level to that seen with the comparator medicines.
Estonian: NovoNorm põhjustas kõikides uuringutes HbA1c taseme vähenemist, mis näitas, et glükoosi sisaldust veres suudeti mõjustada võrdlusravimitega samasel määral.
English: The most common side effects with NovoNorm (seen in between 1 and 10 patients in 100) are hypoglycaemia (low blood glucose levels), abdominal (tummy) pain and diarrhoea.
Estonian: NovoNormi kõige sagedamad kõrvalnähud (esinenud ühel kuni kümnel patsiendil sajast) on hüpoglükeemia (vere vähene glükoosisisaldus), kõhuvalu ja kõhulahtisus.
English: Why has NovoNorm been approved?
Estonian: Miks NovoNorm heaks kiideti?
English: What is the risk associated with NovoNorm?
Estonian: Mis riskid NovoNormiga kaasnevad?
English: NovoNorm should not be used in people who may be hypersensitive (allergic) to repaglinide or any of the other ingredients.
Estonian: NovoNormi ei tohi kasutada patsiendid, kes on repagliniidi või selle ravimi mõne muu koostisaine suhtes ülitundlikud (allergilised).
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Estonian: NovoNormi kasutatakse koos dieedi ja kehaliste harjutustega vereglükoosi (-suhkru) sisalduse vähendamiseks patsientidel, kelle hüperglükeemiat (kõrget veresuhkrut) ei ole võimalik ainuüksi dieedi, kaalu alandamise ja kehaliste harjutustega kontrolli all hoida.
English: NovoNorm has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Estonian: NovoNormi toimet organismis on uuriti 45 kliinilis-farmakoloogilises uuringus ja selle efektiivsust II tüüpi suhkurtõvega patsientide ravis 16 kliinilise katse käigus.
English: NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Estonian: NovoNormi võib kasutada ka nendel II tüüpi suhkurtõvega patsientidel, kelle veresuhkru sisaldus on ajutiselt kontrolli alt väljunud, kuid on tavaliselt reguleeritav dieediga.
English: The full EPAR for NovoNorm is available here.
Estonian: Euroopa avaliku hindamisaruande täisteksti NovoNormi kohta leiate siit.
English: A total of 2,156 patients received NovoNorm in all trials combined.
Estonian: Kõigis katsetes kokku manustati NovoNormi 2156 patsiendile.
English: What benefit has NovoNorm shown during the studies?
Estonian: Milles seisnes uuringute põhjal NovoNormi kasulikkus?
English: NovoNorm helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Estonian: NovoNorm soodustab söögi ajal kõhunäärmes insuliini tekkimist ning seda kasutatakse II tüüpi suhkurtõve raviks.
English: The full list of these medicines is available in the Package Leaflet.
Estonian: Täieliku loetelu leiate pakendi infolehelt.
English: How is NovoNorm used?
Estonian: Kuidas NovoNormi kasutatakse?
English: NovoNorm is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Estonian: NovoNormi kasutatakse II tüüpi suhkurtõvega (insuliinisõltumatu suhkurtõvega) patsientide raviks.
English: How does NovoNorm work?
Estonian: Kuidas NovoNorm toimib?
English: What is NovoNorm used for?
Estonian: Milleks NovoNormi kasutatakse?
English: NovoNorm produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients, leading to a blood glucose-lowering effect throughout the meal.
Estonian: NovoNorm tekitas väga hea insuliinireaktsiooni einele 30 minutit pärast selle manustamist II tüüpi suhkurtõvega patsientidele.
English: How has NovoNorm been studied?
Estonian: Kuidas NovoNormi uuriti?
English: NovoNorm may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Estonian: II tüüpi suhkurtõvega patsientidel, kelle veresuhkru sisaldust ainult metformiiniga ei ole võimalik ohjata, võib NovoNormi kasutada koos metformiiniga (samuti suhkurtõve ravim).
English: Immediate Packaging Pack size
Estonian: 10 mg Õhukese polümeerikattega tablet
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Estonian: I lisa Ravimite nimetused, ravimvormi(de), tugevus(t)e, manustamistee(de), müügiloa hoidja(te) loetelu liikmesriikides
English: TAMIK, capsule soft capsule
Estonian: TAMIK, capsule pehmekapsel
English: Tablets
Estonian: tabletid
English: 2.5 mg tablet
Estonian: 2.5 mg tablett
English: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution oral use ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Estonian: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml suukaudsed tilgad, lahus ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: SEGLOR 5 mg, gélule 5 mg hard capsule
Estonian: SEGLOR 5 mg, gélule 5 mg kõvakapsel
English: SEGLOR LYOC 5 mg, lyophilisat oral oral lyophilisate
Estonian: SEGLOR LYOC 5 mg, lyophilisat oral suukaudne lüofilisaat suukaudne
English: DHE "ratiopharm" 2,5 mg - Kapseln prolonged-release capsule, hard ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Estonian: DHE "ratiopharm" 2,5 mg - Kapseln ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: DET MS Tropflösung 2 mg/ 1 ml
Estonian: DET MS Tropflösung 2 mg/ 1 ml lahus
English: 0.2 g/ 100 ml 1 g/ 100 ml
Estonian: 0.2 g/ 100 ml 1 g/ 100 ml lahus
English: 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX
Estonian: Pierre Fabre Médicaments 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX
English: IKARAN L.P. 5 mg, comprimé à libération prolongée prolonged-release tablet
Estonian: 5 mg, comprimé à libération prolongée toimeainet prolongeeritult vabastav tablett
English: 2 mg/ 1 ml 10 mg/ 1 ml
Estonian: 2 mg/ 1 ml 10 mg/ 1 ml lahus
English: 0.20 g /100 ml oral drops, solution oral use
Estonian: 0.20 g /100 ml suukaudsed tilgad, lahus
English: DHE "ratiopharm" 5 mg - Kapseln prolonged-release capsule, hard
Estonian: DHE "ratiopharm" 5 mg - Kapseln
English: Dihydroergotaminum Filofarm2 mg/g oral solution
Estonian: Dihydroergotaminum Filofarm2 mg/g suukaudne lahus
English: 0.20 g /100 ml oral solution
Estonian: 0.20 g /100 ml suukaudne lahus
English: tablets
Estonian: Orstanorm tabletid
English: Ergovasan 5 mg retard - Kapseln prolonged-release capsule, hard
Estonian: Ergovasan 5 mg retard - Kapseln
English: 2 mg/ 1 ml solution
Estonian: 2 mg/ 1 ml lahus
English: 2 mg/ml oral drops, solution oral use
Estonian: 2 mg/ml suukaudsed tilgad, lahus
English: Ergovasan 2,5 mg retard - Kapseln prolonged-release capsule, hard
Estonian: Ergovasan 2,5 mg retard - Kapseln
English: Ergotam-CT 2,5mg Retardkapseln
Estonian: Ergotam-CT 2,5mg Retardkapseln toimeainet prolongeeritult vabastav kapsel
English: Ergotam-CT 5,0mg Retardkapseln
Estonian: Ergotam-CT 5,0mg Retardkapseln toimeainet prolongeeritult vabastav kapsel
English: modifiedreleasecapsule, hard
Estonian: toimeainet modifitseeritult vabastav kõvakapsel
English: Strength
Estonian: Sisu
English: Pharmaceutical Form Route of administration
Estonian: Ravimvorm Manustamisviis Pakend
English: Invented name
Estonian: Ravimi nimetus Tugevus
English: 3750 U
Estonian: 3750 ühikut
English: Powder for solution for injection/infusion
Estonian: 5 ml süste/infusioonilahuse pulber intramuskulaarne, intravenoosne
English: Solution for injection/infusion
Estonian: Pakendi suurus süste-/infusioonilahus intramuskulaarne, intravenoosne
English: What measures are being taken to ensure the safe and effective use of Cimzia?
Estonian: Mis meetmed võetakse, et tagada Cimzia ohutu ja efektiivne kasutamine?
English: Cimzia received a marketing authorisation valid throughout the EU on 1 October 2009.
Estonian: Cimzia on saanud müügiloa, mis kehtib kogu ELis, 1. oktoobril 2009.